CYP2D6 genotyping in breast cancer patients by liquid chromatography-electrospray ionization mass spectrometry

Beer,B.; Plattner,S.; Hubalek,M.; Oberguggenberger,A.; Sztankay,M.; Meraner,V.; Achleitner,R.; Oberacher,H.
The application of Cytochrome P450 2D6 (CYP2D6) genotyping to allow a personalized treatment approach for breast cancer patients undergoing endocrine therapy has been repeatedly discussed. However, the actual clinical relevance of the CYP2D6 genotype in the endocrine treatment of breast cancer still remains to be elucidated. A major prerequisite for the successful and valid evaluation of the CYP2D6 genotype with respect to its pharmacokinetic and clinical relevance is the availability of a comprehensive, accurate and cost-effective CYP2D6 genotyping strategy. Herein we present a CYP2D6 genotyping assay employing polymerase chain reaction (PCR) - ion-pair reversed-phase high-performance liquid chromatography - electrospray ionization time of flight mass spectrometry (ICEMS). The genotyping strategy involves the simultaneous amplification of nine variable regions within the CYP2D6 gene by a two-step PCR protocol and the direct analysis of the generated PCR amplicons by ICEMS. The nucleotide composition profiles generated by ICEMS enable the differentiation of 37 of the 80 reported CYP2D6 alleles. The assay was applied to type the CYP2D6 gene in 199 Austrian individuals including 106 breast cancer patients undergoing tamoxifen treatment. The developed method turned out to be a highly applicable, robust and cost-effective approach, enabling an economic CYP2D6 testing for large patient cohorts.
HORMONE BIOLOGY AND CLINICAL INVESTIGATION 2011 6(3):247-253
Tags: Breast; CYP2D6; genotyping; mass spectrometry
Home » Research » Publications » Detail